SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
Conclusions
We demonstrated in vitro that PTPRC is a direct target of hsa-miR-363-3p. Using combined
transcriptomic and proteomic high throughput approaches, we identified overexpression of
hsa-miR-363-3p as a potential novel mechanism of repression of PTPRC tumor suppressor
gene in T-ALL.
This work was supported by the National Science Center, Poland, grants:
2014/15/B/NZ2/03394 and 2017/25/N/NZ2/01132, and by the National Centre for Research
and Development, Poland: STRATEGMED3/304586/5/NCBR/2017.
